398 related articles for article (PubMed ID: 17641984)
21. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later.
Deloire M; Ruet A; Hamel D; Bonnet M; Brochet B
Mult Scler; 2010 May; 16(5):581-7. PubMed ID: 20194578
[TBL] [Abstract][Full Text] [Related]
22. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
[TBL] [Abstract][Full Text] [Related]
23. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute relapses in multiple sclerosis at home with oral dexamethasone: a pilot study.
De Keyser J ; Zwanikken CM; Zorgdrager A; Oenema D; Boon M
J Clin Neurosci; 1999 Sep; 6(5):382-384. PubMed ID: 10844776
[TBL] [Abstract][Full Text] [Related]
25. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up.
Bergamaschi R; Versino M; Raiola E; Citterio A; Cosi V
Acta Neurol (Napoli); 1993 Feb; 15(1):33-43. PubMed ID: 8456594
[TBL] [Abstract][Full Text] [Related]
26. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
27. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
28. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
29. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
[TBL] [Abstract][Full Text] [Related]
30. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
31. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
[TBL] [Abstract][Full Text] [Related]
32. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
33. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
34. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy.
Ozakbas S; Akdede BB; Kösehasanogullari G; Aksan O; Idiman E
J Neurol Sci; 2007 May; 256(1-2):30-4. PubMed ID: 17379247
[TBL] [Abstract][Full Text] [Related]
35. Multiple sclerosis: relapses and timing of remissions.
Iuliano G; Napoletano R; Esposito A
Eur Neurol; 2008; 59(1-2):44-8. PubMed ID: 17917457
[TBL] [Abstract][Full Text] [Related]
36. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
37. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
Barnes D; Hughes RA; Morris RW; Wade-Jones O; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi H; Farmer S; Frankel J
Lancet; 1997 Mar; 349(9056):902-6. PubMed ID: 9093250
[TBL] [Abstract][Full Text] [Related]
38. Short-term effects of prolonged fasting on multiple sclerosis.
Saadatnia M; Etemadifar M; Fatehi F; Ashtari F; Shaygannejad V; Chitsaz A; Maghzi AH
Eur Neurol; 2009; 61(4):230-2. PubMed ID: 19176964
[TBL] [Abstract][Full Text] [Related]
39. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
[TBL] [Abstract][Full Text] [Related]
40. A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients.
Sauter C; Zebenholzer K; Hisakawa J; Zeitlhofer J; Vass K
Mult Scler; 2008 May; 14(4):500-5. PubMed ID: 18208883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
